bladder cancer - search results

A urine-based test that detects mutations in 60 genes was shown to predict bladder cancer up to 12 years before diagnosis.

Researchers report that they had found a subset of CD8 T cells in bladder cancer that adapt to tumor evasion strategies by appropriating innate-like properties traditionally ascribed to natural killer cells.

Investigators at the Cedars-Sinai Cancer Center have identified genetic signatures that may help predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.

Results from the CheckMate 274 trial show that adjuvant immunotherapy with nivolumab after surgery and chemotherapy helped reduce bladder cancer recurrence in patients with urothelial cancer of the bladder.

Adding the anti-inflammatory medication celecoxib to immunotherapy and standard chemotherapy drugs appears to suppress aggressive bladder tumor growth, according to a proof-of-concept study led by investigators from Cedars-Sinai Medical Center.

A Mount Sinai research team has identified genotypes associated with sensitivity and resistance to cancer immunotherapy in patients with metastatic urothelial cancer of the bladder, as well a specific type of white blood cell that helps promote cancer-related inflammation in some people.

This single-arm Phase II study investigating two cycles of atezolizumab achieved the primary efficacy endpoint, showing a pathological complete response rate of 31%.

Liquid biopsy using urine is better than testing blood when it comes to accurately reflecting the genomic profile of bladder cancer tumors. That’s according...

MDxHealth has launched its AssureMD for Bladder Cancer test in the U.S. as a laboratory developed test (LDT).

Urine biomarker test detects urothelial bladder cancer, predicts likelihood of recurrence earlier and more accurately than current methods